ClinicalTrials.gov Identifier
SOLID TUMORS
NCT03508011This phase I, first-in-human, dose-escalation/-expansion study explored the pharmacokinetics, safety, and tolerability, and preliminary antitumor activity of senaparib in Chinese patients with advanced solid tumors.